Key points are not available for this paper at this time.
The LMO2 oncogene causes a subset of human T cell acute lymphoblastic leukemias (T-ALL), including four cases that arose as adverse events in gene therapy trials. To investigate the cellular origin of LMO2-induced leukemia, we used cell fate mapping to study mice in which the Lmo2 gene was constitutively expressed in the thymus. Lmo2 induced self-renewal of committed T cells in the mice more than 8 months before the development of overt T-ALL. These self-renewing cells retained the capacity for T cell differentiation but expressed several genes typical of hematopoietic stem cells (HSCs), suggesting that Lmo2 might reactivate an HSC-specific transcriptional program. Forced expression of one such gene, Hhex, was sufficient to initiate self-renewal of thymocytes in vivo. Thus, Lmo2 promotes the self-renewal of preleukemic thymocytes, providing a mechanism by which committed T cells can then accumulate additional genetic mutations required for leukemic transformation.
Building similarity graph...
Analyzing shared references across papers
Loading...
Matthew P. McCormack
Lauren Young
Sumitha Vasudevan
Science
The University of Melbourne
Building similarity graph...
Analyzing shared references across papers
Loading...
McCormack et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69da9b1e85037e71b26842de — DOI: https://doi.org/10.1126/science.1182378
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: